🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. Panzem Nanocrystal Colloidal Dispersion

    CASI Pharmaceuticals

    Recurrent Glioblastoma Multiforme

    phase 2 small molecule completed

    1 trial

  2. Panzem Nanocrystal Colloidal Dispersion (NCD)

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  3. Panzem® NCD

    CASI Pharmaceuticals

    Metastatic Renal Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  4. Panzem® NCD

    CASI Pharmaceuticals

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  5. Para-Tabs 500 mg tabletti, ODM-111 Placebo, ODM-111, ODM-111

    Orion Laboratories Pty.

    CHRONIC PAIN DUE TO DIABETIC PERIPHERAL NEUROPATHY

    phase 2 small molecule active

    1 trial

  6. Paracetamol/Codeine phosphate hemihydrate Accord 500 mg/30 mg tablets, PARACETAMOL, DFV890, Placebo to DFV890 10mg, Placebo to DFV890 25mg, DFV890

    Novartis Pharmaceuticals

    Knee Osteoarthritis

    phase 2 small molecule active

    1 trial

  7. Part 1: VP-315 3 Day Dosing/Week

    Verrica Pharmaceuticals

    Basal Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  8. Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 2 small molecule active

    1 trial

  9. Patupilone

    Novartis Pharmaceuticals

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  10. Pedmark® STS

    FENNEC PHARMACEUTICALS INC.

    Solid Tumor Malignancies

    phase 2 small molecule active

    1 trial

  11. Pembrolizumab

    Syndax Pharmaceuticals

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  12. Pembrolizumab

    Syndax Pharmaceuticals

    Metastatic Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  13. Pentasa Sachet 2 g depotgranulat, Pentasa PLACEBO Sachet 2g in the granule formulation specifically designed to resemble the active drug product

    The George Institute

    Lynch syndrome, which is increasing the risk of developing colorectal cancer

    phase 2 small molecule active

    1 trial

  14. Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.

    NovoThirteen

    Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.

    phase 2 other active

    1 trial

  15. Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy.

    NovoThirteen

    Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left Ventricular Hypertrophy.

    phase 2 other active

    1 trial

  16. Phase I/II safety, tolerability and initial efficacy study of adeno-associated viral vector serotype 9 containing human sulfamidase gene after intracerebroventricular administration to patients with MPSIIIA.

    Esteve Pharmaceuticals

    Mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)

    phase 2 other active

    1 trial

  17. Phenoptin

    BioMarin Pharmaceutical Australia Pty Ltd

    Tetrahydrobiopterin Deficiencies

    phase 2 small molecule completed

    1 trial

  18. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  19. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease

    phase 2 small molecule terminated

    1 trial

  20. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Treatment of Depression in Adults With Parkinson's Disease (PD)

    phase 2 small molecule completed

    1 trial

  21. Pimavanserin 34 mg

    Acadia Pharmaceuticals B.V.

    Intermittent Explosive Disorder

    phase 2 small molecule active

    1 trial

  22. Pimavanserin 34 mg

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  23. Pimavanserin 34 milligrams (MG) [Nuplazid]

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  24. Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]

    Acadia Pharmaceuticals B.V.

    Autism Spectrum Disorder

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources